BIOCAD will invest $26 million in infrastructure for gene therapies development

| By | Biocad, Cancer Drugs, Gene Therapy

The agreements on collaboration and joint research in the area of adoptive immunotherapy (CAR T-cell therapy) were signed between V.A. Almazov National Medical Research Center and BIOCAD, a biotech company, on May 24, 2018 at the St. Petersburg International Economic Forum.

CAR T-cell therapy is based on the use of patient’s own genetically modified T-lymphocytes able to recognize tumor cells.

According to Dmitry Morozov, General Director of BIOCAD, the cost of manufacturing individual formulation for one patient will not exceed 16 million rubles, which is two times less expensive than in Western clinics. After the treatment, the patient will not require additional therapy for three years and will need only periodic follow-up with a doctor.

The Russian Ministry of Health plans to build, together with BIOCAD, a clinic related to the V.A. Almazov National Medical Research Center, where the cancer patients will be treated with personalized biomedical cell products. BIOCAD estimates that the infrastructure to develop gene therapy will cost $26 million, which the company expects to invest within two years.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.